<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Written evidence submitted by the Sustainable Food Trust (AMR0056)</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">the Sustainable Food Trust </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">(AMR0056)</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Executive </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Summary</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 82.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Antimicrobial resistance is an</span><span style="font-family:'Times New Roman'; font-size:11pt"> increasing problem and extreme care in the use of antimicrobials is now needed in all sectors since there are unlikely to be new antimicrobials for some serious infections for many years</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 82.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">he Government’s 5-Year Strategy on </span><span style="font-family:'Times New Roman'; font-size:11pt">antimicrobial resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> lacks t</span><span style="font-family:'Times New Roman'; font-size:11pt">he detail and commitment to address specific resistance and usage issues associated with food and food animals</span><span style="font-family:'Times New Roman'; font-size:11pt"> of significance to humans</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 82.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Farm use of three critically important</span><span style="font-family:'Times New Roman'; font-size:11pt"> antimicrobial (CIAs) </span><span style="font-family:'Times New Roman'; font-size:11pt">in human medicine (fluoroquinolones, modern cephalosporins</span><span style="font-family:'Times New Roman'; font-size:11pt"> and macrolides) continues to rise. Resistant bacteria from farm animals, including E. coli, salmonella, campylobacter, enterococci and MRSA, can all contribute to treatment problems in human medicine.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 82.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Government has no credible strategy for reducing </span><span style="font-family:'Times New Roman'; font-size:11pt">f</span><span style="font-family:'Times New Roman'; font-size:11pt">arm use or the</span><span style="font-family:'Times New Roman'; font-size:11pt"> levels of multi-drug resistant</span><span style="font-family:'Times New Roman'; font-size:11pt"> infections</span><span style="font-family:'Times New Roman'; font-size:11pt"> in food animals. There is an urgent need</span><span style="font-family:'Times New Roman'; font-size:11pt"> to reduce the level of ESBL resistance in E. coli infections and the risk of ESBL resistance transferring to gonorrhoea, which would impose a significant burd</span><span style="font-family:'Times New Roman'; font-size:11pt">en on the NHS.</span></li></ul><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 72pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Key recommendations</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 82.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The strategy should contain a commitment to phase out the routine preventative use of antimicrobials in animals where no disease is present and impose restrictions on the use of modern cephalosporins and fluoroquinolones</span><span style="font-family:'Times New Roman'; font-size:11pt"> in particular. </span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 82.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The structure, role and responsibilities of the Veterinary Medicines Directorate (VMD) need to be reviewed. Responsibility for antimicrobial resistance in farm animals and policy on veterinary medicines was taken from Defra and handed to t</span><span style="font-family:'Times New Roman'; font-size:11pt">he VMD in 2011. This raises a wide range of issues, because the funding structure of the VMD means that it needs to attract an increasing share of </span><span style="font-family:'Times New Roman'; font-size:11pt">industry funding </span><span style="font-family:'Times New Roman'; font-size:11pt">f</span><span style="font-family:'Times New Roman'; font-size:11pt">or EU</span><span style="font-family:'Times New Roman'; font-size:11pt"> licensing work. This makes it institutionally vulnerable to industry lobbying and pre</span><span style="font-family:'Times New Roman'; font-size:11pt">ssure.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 82.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There is a need for an independent, permanent</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> over-arching scientific committee to be responsible for advising Ministers on all aspects of antimicrobial use </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span><span style="font-family:'Times New Roman'; font-size:11pt"> resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> covering both human and veterinary medicine</span><span style="font-family:'Times New Roman'; font-size:11pt">. There is also a need for </span><span style="font-family:'Times New Roman'; font-size:11pt">ongoing Parliamentary scrutiny of the Government’s efforts to address these issues</span><span style="font-family:'Times New Roman'; font-size:11pt"> and</span><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt"> react in a timely manner to emerging is</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt">ues</span><span style="font-family:'Times New Roman'; font-size:11pt">. The House of Lords Science and Technology committee made far-reaching and important recommendations in 1998</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> but failed to k</span><span style="font-family:'Times New Roman'; font-size:11pt">eep an eye on the situation after 2001. </span></li></ul><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 49.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Introduction</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2.1 </span><span style="font-family:'Times New Roman'; font-size:11pt">The Sustainabl</span><span style="font-family:'Times New Roman'; font-size:11pt">e Food Trust (SFT) </span><span style="font-family:'Times New Roman'; font-size:11pt">was</span><span style="font-family:'Times New Roman'; font-size:11pt"> established in 2011 to help accelerate the transition to more durable</span><span style="font-family:'Times New Roman'; font-size:11pt"> and</span><span style="font-family:'Times New Roman'; font-size:11pt"> benign</span><span style="font-family:'Times New Roman'; font-size:11pt"> food production</span><span style="font-family:'Times New Roman'; font-size:11pt">. We welcome</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">this opportunity to comment on</span><span style="font-family:'Times New Roman'; font-size:11pt"> the issue of antimi</span><span style="font-family:'Times New Roman'; font-size:11pt">crobial resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> (AMR)</span><span style="font-family:'Times New Roman'; font-size:11pt"> and</span><span style="font-family:'Times New Roman'; font-size:11pt"> will concentrate on</span><span style="font-family:'Times New Roman'; font-size:11pt"> those aspects that </span><span style="font-family:'Times New Roman'; font-size:11pt">relate to</span><span style="font-family:'Times New Roman'; font-size:11pt"> the </span><span style="font-family:'Times New Roman'; font-size:11pt">development of AMR</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">in</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">food animals</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2.2 </span><span style="font-family:'Times New Roman'; font-size:11pt">The author of this </span><span style="font-family:'Times New Roman'; font-size:11pt">submission</span><span style="font-family:'Times New Roman'; font-size:11pt"> declares an interest as he </span><span style="font-family:'Times New Roman'; font-size:11pt">is an organic </span><span style="font-family:'Times New Roman'; font-size:11pt">beef and sheep </span><span style="font-family:'Times New Roman'; font-size:11pt">farmer</span><span style="font-family:'Times New Roman'; font-size:11pt"> and </span><span style="font-family:'Times New Roman'; font-size:11pt">has</span><span style="font-family:'Times New Roman'; font-size:11pt"> been involved in the development of organic </span><span style="font-family:'Times New Roman'; font-size:11pt">farming </span><span style="font-family:'Times New Roman'; font-size:11pt">standards</span><span style="font-family:'Times New Roman'; font-size:11pt"> in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt">, which restrict the use of antibiotics on organic farms</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 49.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">How has antimicrobial resistance developed in the past decade?</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3.1 It might be more helpful to consider how </span><span style="font-family:'Times New Roman'; font-size:11pt">AMR</span><span style="font-family:'Times New Roman'; font-size:11pt"> has developed over the last 15 years, since</span><span style="font-family:'Times New Roman'; font-size:11pt">, although the issue was briefly revisited by the House of Lords Science and Technology Committee in its third report in 2001</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[1]</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> this more closely equates to the period since </span><span style="font-family:'Times New Roman'; font-size:11pt">a </span><span style="font-family:'Times New Roman'; font-size:11pt">Parliament</span><span style="font-family:'Times New Roman'; font-size:11pt">ary committee</span><span style="font-family:'Times New Roman'; font-size:11pt"> last gave </span><span style="font-family:'Times New Roman'; font-size:11pt">serious </span><span style="font-family:'Times New Roman'; font-size:11pt">consideration to </span><span style="font-family:'Times New Roman'; font-size:11pt">AMR</span><span style="font-family:'Times New Roman'; font-size:11pt"> in 1998</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[2]</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and the ACMSF produced a repo</span><span style="font-family:'Times New Roman'; font-size:11pt">rt </span><span style="font-family:'Times New Roman'; font-size:11pt">on this </span><span style="font-family:'Times New Roman'; font-size:11pt">in 1999 </span><span style="font-family:'Times New Roman'; font-size:11pt">[3]</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3.2 </span><span style="font-family:'Times New Roman'; font-size:11pt">Although AMR is an inevitable co</span><span style="font-family:'Times New Roman'; font-size:11pt">nsequence of antimicrobial use </span><span style="font-family:'Times New Roman'; font-size:11pt">there has</span><span style="font-family:'Times New Roman'; font-size:11pt"> been an unprecedent</span><span style="font-family:'Times New Roman'; font-size:11pt">ed </span><span style="font-family:'Times New Roman'; font-size:11pt">increase in the </span><span style="font-family:'Times New Roman'; font-size:11pt">number of</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">farming-related </span><span style="font-family:'Times New Roman'; font-size:11pt">AMR developments.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">We have seen</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 108pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">3.2.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">the emerg</span><span style="font-family:'Times New Roman'; font-size:11pt">ence of fluoroquinolone resistance in Campylobacter</span><span style="font-family:'Times New Roman'; font-size:11pt"> in poultry and pigs</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[4]</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> which is contributing to the rise of fl</span><span style="font-family:'Times New Roman'; font-size:11pt">u</span><span style="font-family:'Times New Roman'; font-size:11pt">oroquinolone resistance in campylobacter infec</span><span style="font-family:'Times New Roman'; font-size:11pt">tions in humans</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[5]</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 108pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 108pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">3.2.2</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">fluoroquinolone resistance in salmonella</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[6]</span><span style="font-family:'Times New Roman'; font-size:11pt">[7]</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and the</span><span style="font-family:'Times New Roman'; font-size:11pt"> emergence of plasmids carrying</span><span style="font-family:'Times New Roman'; font-size:11pt"> fluoroqui</span><span style="font-family:'Times New Roman'; font-size:11pt">nolone resistance in salmonella</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">P</span><span style="font-family:'Times New Roman'; font-size:11pt">lasmids are mobile genes that </span><span style="font-family:'Times New Roman'; font-size:11pt">readily</span><span style="font-family:'Times New Roman'; font-size:11pt"> pass resistance fro</span><span style="font-family:'Times New Roman'; font-size:11pt">m one bacterium to another</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 108pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 108pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">3.2.3</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">a significant ris</span><span style="font-family:'Times New Roman'; font-size:11pt">e in AMR in E.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">coli urinary</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">tract infections</span><span style="font-family:'Times New Roman'; font-size:11pt"> (UTIs)</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">in humans </span><span style="font-family:'Times New Roman'; font-size:11pt">[8]</span><span style="font-family:'Times New Roman'; font-size:11pt">[9]</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">F</span><span style="font-family:'Times New Roman'; font-size:11pt">o</span><span style="font-family:'Times New Roman'; font-size:11pt">o</span><span style="font-family:'Times New Roman'; font-size:11pt">d is recognized as an important source of AMR ge</span><span style="font-family:'Times New Roman'; font-size:11pt">nes in the human gut</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and the E.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">coli causing UTIs are faecal in origin</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">It has been estimated there are </span><span style="font-family:'Times New Roman'; font-size:11pt">more than</span><span style="font-family:'Times New Roman'; font-size:11pt"> 750,000 E. coli infections every year in the UK, most of which will be UTIs</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[10]</span><span style="font-family:'Times New Roman'; font-size:11pt">. Treatment failures </span><span style="font-family:'Times New Roman'; font-size:11pt">in the UK </span><span style="font-family:'Times New Roman'; font-size:11pt">due to the rise in AMR in UTIs have</span><span style="font-family:'Times New Roman'; font-size:11pt"> contributed to </span><span style="font-family:'Times New Roman'; font-size:11pt">a</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">4-fold increase in E. coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">blood poisoning</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">over the last 20 years</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> to approx</span><span style="font-family:'Times New Roman'; font-size:11pt">im</span><span style="font-family:'Times New Roman'; font-size:11pt">ately 40,000 cases annually</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and an increase i</span><span style="font-family:'Times New Roman'; font-size:11pt">n mortality to approximately 8,0</span><span style="font-family:'Times New Roman'; font-size:11pt">00 deaths </span><span style="font-family:'Times New Roman'; font-size:11pt">each year</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 108pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 108pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">3.2.4</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">the emergence of ESBL (extended spectrum beta lactamase) resistan</span><span style="font-family:'Times New Roman'; font-size:11pt">t E. coli </span><span style="font-family:'Times New Roman'; font-size:11pt">I</span><span style="font-family:'Times New Roman'; font-size:11pt">n UK farm animals</span><span style="font-family:'Times New Roman'; font-size:11pt"> and imported chicken</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[10]</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and </span><span style="font-family:'Times New Roman'; font-size:11pt">its spread to salmonella and klebsiella.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 72pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 108pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">3.2.6</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">the emergence of </span><span style="font-family:'Times New Roman'; font-size:11pt">livestock-associated </span><span style="font-family:'Times New Roman'; font-size:11pt">(LA) </span><span style="font-family:'Times New Roman'; font-size:11pt">strains of MRSA </span><span style="font-family:'Times New Roman'; font-size:11pt">which </span><span style="font-family:'Times New Roman'; font-size:11pt">have the </span><span style="font-family:'Times New Roman'; font-size:11pt">ability to colonize, pass between </span><span style="font-family:'Times New Roman'; font-size:11pt">and cause infection in farm anim</span><span style="font-family:'Times New Roman'; font-size:11pt">als and humans</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[11]</span><span style="font-family:'Times New Roman'; font-size:11pt">. In the UK</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">MRSA </span><span style="font-family:'Times New Roman'; font-size:11pt">ST398 has been </span><span style="font-family:'Times New Roman'; font-size:11pt">found </span><span style="font-family:'Times New Roman'; font-size:11pt">in milk</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">on </span><span style="font-family:'Times New Roman'; font-size:11pt">dairy farms</span><span style="font-family:'Times New Roman'; font-size:11pt"> and in horses </span><span style="font-family:'Times New Roman'; font-size:11pt">[12]</span><span style="font-family:'Times New Roman'; font-size:11pt">[13]</span><span style="font-family:'Times New Roman'; font-size:11pt">. It has also been found in a small number of human cases </span><span style="font-family:'Times New Roman'; font-size:11pt">[14]</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 72pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 108pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">3.2.7</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">the discovery of</span><span style="font-family:'Times New Roman'; font-size:11pt"> an entirely new type of MRSA in dairy cows and humans</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">with a </span><span style="font-family:'Times New Roman'; font-size:11pt">m</span><span style="font-family:'Times New Roman'; font-size:11pt">ecC </span><span style="font-family:'Times New Roman'; font-size:11pt">resistance </span><span style="font-family:'Times New Roman'; font-size:11pt">gene</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> as opposed to a </span><span style="font-family:'Times New Roman'; font-size:11pt">m</span><span style="font-family:'Times New Roman'; font-size:11pt">ecA gene</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[15]</span><span style="font-family:'Times New Roman'; font-size:11pt">[16]</span><span style="font-family:'Times New Roman'; font-size:11pt">. It </span><span style="font-family:'Times New Roman'; font-size:11pt">has been </span><span style="font-family:'Times New Roman'; font-size:11pt">estimated </span><span style="font-family:'Times New Roman'; font-size:11pt">this</span><span style="font-family:'Times New Roman'; font-size:11pt"> could</span><span style="font-family:'Times New Roman'; font-size:11pt"> be responsible for 1</span><span style="font-family:'Times New Roman'; font-size:11pt">-4</span><span style="font-family:'Times New Roman'; font-size:11pt">% of </span><span style="font-family:'Times New Roman'; font-size:11pt">Danish human MRSA cases. I</span><span style="font-family:'Times New Roman'; font-size:11pt">t also causes human infections in England and Scotland</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[15]</span><span style="font-family:'Times New Roman'; font-size:11pt">[17]</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 72pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 108pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">3.2.8</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">emergence of </span><span style="font-family:'Times New Roman'; font-size:11pt">carbapenem</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">resistant </span><span style="font-family:'Times New Roman'; font-size:11pt">infections</span><span style="font-family:'Times New Roman'; font-size:11pt"> in humans, and </span><span style="font-family:'Times New Roman'; font-size:11pt">isolated </span><span style="font-family:'Times New Roman'; font-size:11pt">reports </span><span style="font-family:'Times New Roman'; font-size:11pt">of </span><span style="font-family:'Times New Roman'; font-size:11pt">carbapenem-resistan</span><span style="font-family:'Times New Roman'; font-size:11pt">t </span><span style="font-family:'Times New Roman'; font-size:11pt">bacteria in farm animals </span><span style="font-family:'Times New Roman'; font-size:11pt">[18]</span><span style="font-family:'Times New Roman'; font-size:11pt">[19]</span><span style="font-family:'Times New Roman'; font-size:11pt">[20]</span><span style="font-family:'Times New Roman'; font-size:11pt">. This has </span><span style="font-family:'Times New Roman'; font-size:11pt">possibly spread from humans to farm animals</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">but the use of farm antibiotics </span><span style="font-family:'Times New Roman'; font-size:11pt">can </span><span style="font-family:'Times New Roman'; font-size:11pt">‘co-select’ for carbapenem</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">res</span><span style="font-family:'Times New Roman'; font-size:11pt">istant bacteria once present</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[21]</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 72pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 108pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">3.2.9</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">the emergence of </span><span style="font-family:'Times New Roman'; font-size:11pt">the</span><span style="font-family:'Times New Roman'; font-size:11pt"> new epidemic multi-drug resistant </span><span style="font-family:'Times New Roman'; font-size:11pt">(monophasic)  </span><span style="font-family:'Times New Roman'; font-size:11pt">salmonella typhimurium </span><span style="font-family:'Times New Roman'; font-size:11pt">in pigs and other farm animals</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">which is </span><span style="font-family:'Times New Roman'; font-size:11pt">causing</span><span style="font-family:'Times New Roman'; font-size:11pt"> infections in humans </span><span style="font-family:'Times New Roman'; font-size:11pt">[22]</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 72pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 108pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">3.2.10</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">the emergence of linezolid resistance in staphylococci and enterococci in </span><span style="font-family:'Times New Roman'; font-size:11pt">both humans and animals and the emergence of plasmid-</span><span style="font-family:'Times New Roman'; font-size:11pt">mediated</span><span style="font-family:'Times New Roman'; font-size:11pt"> linezolid resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[23]</span><span style="font-family:'Times New Roman'; font-size:11pt">. Linezolid is an antibiotic of last resort for treating infections such as MRSA and VRE. </span><span style="font-family:'Times New Roman'; font-size:11pt">It </span><span style="font-family:'Times New Roman'; font-size:11pt">is not used in agriculture, but the veterinary antibiotic florfencol is cross-resistant</span><span style="font-family:'Times New Roman'; font-size:11pt"> with linezolid</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[24]</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 72pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 108pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">3.2.11</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">AMR is also steadily becoming a problem for the effective treatment of farm </span><span style="font-family:'Times New Roman'; font-size:11pt">animals. </span><span style="font-family:'Times New Roman'; font-size:11pt">R</span><span style="font-family:'Times New Roman'; font-size:11pt">esistance to tetracyclines, sulphonomides</span><span style="font-family:'Times New Roman'; font-size:11pt"> and ampicillin </span><span style="font-family:'Times New Roman'; font-size:11pt">has</span><span style="font-family:'Times New Roman'; font-size:11pt"> been </span><span style="font-family:'Times New Roman'; font-size:11pt">increasing for many years </span><span style="font-family:'Times New Roman'; font-size:11pt">in E. coli</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and the </span><span style="font-family:'Times New Roman'; font-size:11pt">rise</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and spread </span><span style="font-family:'Times New Roman'; font-size:11pt">of ESBL E.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">coli </span><span style="font-family:'Times New Roman'; font-size:11pt">on</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">British </span><span style="font-family:'Times New Roman'; font-size:11pt">farms </span><span style="font-family:'Times New Roman'; font-size:11pt">could make </span><span style="font-family:'Times New Roman'; font-size:11pt">infections</span><span style="font-family:'Times New Roman'; font-size:11pt"> difficult </span><span style="font-family:'Times New Roman'; font-size:11pt">to treat </span><span style="font-family:'Times New Roman'; font-size:11pt">in future. </span><span style="font-family:'Times New Roman'; font-size:11pt">AMR</span><span style="font-family:'Times New Roman'; font-size:11pt"> has also been increasing in swine dysentery</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">with some cases resistant to all ve</span><span style="font-family:'Times New Roman'; font-size:11pt">terinary antimicrobials including</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">the pleuromuti</span><span style="font-family:'Times New Roman'; font-size:11pt">lin</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[25]</span><span style="font-family:'Times New Roman'; font-size:11pt"> a class of antibiotics being developed for human medicine with the potential for treating MRSA and tuberc</span><span style="font-family:'Times New Roman'; font-size:11pt">ulosis</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[26]</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">The pleuromutalin</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> tiamulin</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> can </span><span style="font-family:'Times New Roman'; font-size:11pt">be added to the feed of egg-</span><span style="font-family:'Times New Roman'; font-size:11pt">laying hens and has a zero withdrawal period. </span><span style="font-family:'Times New Roman'; font-size:11pt">It is not clear what part </span><span style="font-family:'Times New Roman'; font-size:11pt">AMR</span><span style="font-family:'Times New Roman'; font-size:11pt"> played in a m</span><span style="font-family:'Times New Roman'; font-size:11pt">ajor outbreak in East Anglia which affected 24 farms </span><span style="font-family:'Times New Roman'; font-size:11pt">between 2006 and 2009</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> but 3,000 sows had to be slaughtered</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> because they could not be treated effectively</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[27]</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> V</span><span style="font-family:'Times New Roman'; font-size:11pt">eterinary antimicrobials that are used to treat swine dysentery are also permitted for its control</span><span style="font-family:'Times New Roman'; font-size:11pt"> (or in some cases prevention)</span><span style="font-family:'Times New Roman'; font-size:11pt"> at sub-therapeutic levels over prolonged periods. This is li</span><span style="font-family:'Times New Roman'; font-size:11pt">kely to have contributed to the rise of resistance.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 72pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 108pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">3.2.12</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">The House of Lords drew attention to the high use of fluoroquinolones on </span><span style="font-family:'Times New Roman'; font-size:11pt">farms and recommended action</span><span style="font-family:'Times New Roman'; font-size:11pt"> in 1998</span><span style="font-family:'Times New Roman'; font-size:11pt">. This fell</span><span style="font-family:'Times New Roman'; font-size:11pt"> shortly afterwards</span><span style="font-family:'Times New Roman'; font-size:11pt"> as a result</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> but has increased annually since and now st</span><span style="font-family:'Times New Roman'; font-size:11pt">ands at its highest ever level</span><span style="font-family:'Times New Roman'; font-size:11pt">, 2,434 kg of active ingredient</span><span style="font-family:'Times New Roman'; font-size:11pt">. The use of modern (3</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">rd</span><span style="font-family:'Times New Roman'; font-size:11pt"> and 4</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">th</span><span style="font-family:'Times New Roman'; font-size:11pt"> generation) cephalosporins and macrolides on farms also continues to increase. These are defined as critically important antimicrobials </span><span style="font-family:'Times New Roman'; font-size:11pt">(CIAs) </span><span style="font-family:'Times New Roman'; font-size:11pt">in human medicine</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[28]</span><span style="font-family:'Times New Roman'; font-size:11pt">. Additional restrictions </span><span style="font-family:'Times New Roman'; font-size:11pt">on their use are needed.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 126pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 49.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What are the gaps in our knowledge about antimicrobial resistance</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">?</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4.1</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Only one published study has ever </span><span style="font-family:'Times New Roman'; font-size:11pt">looked at the direct effect of food on the levels of </span><span style="font-family:'Times New Roman'; font-size:11pt">resistance in bacteria in the human intestine</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[29]</span><span style="font-family:'Times New Roman'; font-size:11pt">. It found that resistance levels fell very sharply </span><span style="font-family:'Times New Roman'; font-size:11pt">when</span><span style="font-family:'Times New Roman'; font-size:11pt"> food was sterilised, providing strong evidence that food contributes </span><span style="font-family:'Times New Roman'; font-size:11pt">significantly </span><span style="font-family:'Times New Roman'; font-size:11pt">to resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> in some human infections</span><span style="font-family:'Times New Roman'; font-size:11pt">. Because this</span><span style="font-family:'Times New Roman'; font-size:11pt"> was only a small study, a larger study should be undertaken to see if the results are replicated. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4.4 </span><span style="font-family:'Times New Roman'; font-size:11pt">R</span><span style="font-family:'Times New Roman'; font-size:11pt">esearch </span><span style="font-family:'Times New Roman'; font-size:11pt">is needed </span><span style="font-family:'Times New Roman'; font-size:11pt">to establish </span><span style="font-family:'Times New Roman'; font-size:11pt">for the full range of antimicrobials,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">how long after </span><span style="font-family:'Times New Roman'; font-size:11pt">treatment AMR falls back to background levels</span><span style="font-family:'Times New Roman'; font-size:11pt">. This </span><span style="font-family:'Times New Roman'; font-size:11pt">could be used </span><span style="font-family:'Times New Roman'; font-size:11pt">to </span><span style="font-family:'Times New Roman'; font-size:11pt">amend statutory </span><span style="font-family:'Times New Roman'; font-size:11pt">withdrawal </span><span style="font-family:'Times New Roman'; font-size:11pt">periods</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">to help protect consumers against antimicrobial resistance as well as residu</span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">A</span><span style="font-family:'Times New Roman'; font-size:11pt"> Defra-funded project </span><span style="font-family:'Times New Roman'; font-size:11pt">from 2001-2004 concluded, ‘</span><span style="font-family:'Times New Roman'; font-size:11pt">The finding of this study indicate that the risk posed by the antibiotics </span><span style="font-family:'Times New Roman'; font-size:11pt">eva</span><span style="font-family:'Times New Roman'; font-size:11pt">luated coul</span><span style="font-family:'Times New Roman'; font-size:11pt">d be greatly reduced</span><span style="font-family:'Times New Roman'; font-size:11pt"> by increasing the withdrawal period by 7 days for chlortetracycline and enrofloxacin, and introducing a withdrawal period of 3 weeks for tylosin and 2 weeks for avilamycin.</span><span style="font-family:'Times New Roman'; font-size:11pt">’</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[30]</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Follow up research at a cost of £410,000 was carried out which identified additional strategies for reducing AMR in animals at slaughter</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[31]</span><span style="font-family:'Times New Roman'; font-size:11pt">, but this </span><span style="font-family:'Times New Roman'; font-size:11pt">all </span><span style="font-family:'Times New Roman'; font-size:11pt">appears to have been shelved and </span><span style="font-family:'Times New Roman'; font-size:11pt">Tylosin, for example</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> still has a</span><span style="font-family:'Times New Roman'; font-size:11pt"> zero withdrawal period in pigs</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">4.5 </span><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">here is an</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">urgent </span><span style="font-family:'Times New Roman'; font-size:11pt">need to establish</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 59.71pt; padding-left:4.09pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">the potential for ESBL resistance </span><span style="font-family:'Times New Roman'; font-size:11pt">genes in gut bacteria to transfer to </span><span style="font-family:'Times New Roman'; font-size:11pt">gonorrheoa</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 59.71pt; padding-left:4.09pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">the main ways in which ESBL resistance could be reduced in food animals</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 59.71pt; padding-left:4.09pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">the public health and educational means which </span><span style="font-family:'Times New Roman'; font-size:11pt">could </span><span style="font-family:'Times New Roman'; font-size:11pt">also </span><span style="font-family:'Times New Roman'; font-size:11pt">be used to help prevent </span><span style="font-family:'Times New Roman'; font-size:11pt">such a </span><span style="font-family:'Times New Roman'; font-size:11pt">serious </span><span style="font-family:'Times New Roman'; font-size:11pt">development</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ul><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">5.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Is there sufficient res</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">earch and investment into new antibiotics?</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5.1 </span><span style="font-family:'Times New Roman'; font-size:11pt">R</span><span style="font-family:'Times New Roman'; font-size:11pt">esearch should be encouraged, with public funds if necessary</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> into the development of new antimicrobial classes, especially t</span><span style="font-family:'Times New Roman'; font-size:11pt">h</span><span style="font-family:'Times New Roman'; font-size:11pt">ose with Gram-negative action. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">6</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What measures (including behavioural change</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">)</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> have been most effective in controlling the spr</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ead of resistant pathogens and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">what measures could be used to control other pathogens?</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">6.1 </span><span style="font-family:'Times New Roman'; font-size:11pt">As explained above</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">longer</span><span style="font-family:'Times New Roman'; font-size:11pt"> withdrawal periods between treatment and slaughter can dramatically reduce levels of AMR.</span><span style="font-family:'Times New Roman'; font-size:11pt"> This may be more practical for </span><span style="font-family:'Times New Roman'; font-size:11pt">cattle, </span><span style="font-family:'Times New Roman'; font-size:11pt">pigs and free-range poultry than broilers. </span><span style="font-family:'Times New Roman'; font-size:11pt">Reducing stocking density, allowing young animals to develop good immune systems (for example by </span><span style="font-family:'Times New Roman'; font-size:11pt">later </span><span style="font-family:'Times New Roman'; font-size:11pt">weaning</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and reducing stress are all very helpful</span><span style="font-family:'Times New Roman'; font-size:11pt"> in reducing the use </span><span style="font-family:'Times New Roman'; font-size:11pt">of antimicrobials and the levels of resistance in pathogens and commensal bacteria</span><span style="font-family:'Times New Roman'; font-size:11pt">. Defra-funded </span><span style="font-family:'Times New Roman'; font-size:11pt">studies have shown that there are ver</span><span style="font-family:'Times New Roman'; font-size:11pt">y much lower levels of AMR in organically</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">reared animals</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[32]</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Caution is needed </span><span style="font-family:'Times New Roman'; font-size:11pt">with</span><span style="font-family:'Times New Roman'; font-size:11pt"> the use of some disinfectants as these also select for AMR.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What are the strengths and weaknesses of the Government’s 2013-2018 Strategy?</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.1 </span><span style="font-family:'Times New Roman'; font-size:11pt">The SFT welcomes the three</span><span style="font-family:'Times New Roman'; font-size:11pt"> strategic aims, the overall spirit and,</span><span style="font-family:'Times New Roman'; font-size:11pt"> with some qualifications, the seven</span><span style="font-family:'Times New Roman'; font-size:11pt"> key areas for future action in the strategy. However, we </span><span style="font-family:'Times New Roman'; font-size:11pt">also </span><span style="font-family:'Times New Roman'; font-size:11pt">see</span><span style="font-family:'Times New Roman'; font-size:11pt"> a number of serious weaknesses</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify"><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">7</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">.2</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">The strategy should have recognised the need for vets to be </span><span style="font-family:'Times New Roman'; font-size:11pt">required</span><span style="font-family:'Times New Roman'; font-size:11pt"> to adopt antibiotic-prescribing policies, just as the Health Act 2006 introduced such a require</span><span style="font-family:'Times New Roman'; font-size:11pt">ment for hospital prescribing. </span><span style="font-family:'Times New Roman'; font-size:11pt">Vets have the right to ‘prescribe a</span><span style="font-family:'Times New Roman'; font-size:11pt">ccording to their clinical judg</span><span style="font-family:'Times New Roman'; font-size:11pt">ment’ but all</span><span style="font-family:'Times New Roman'; font-size:11pt"> v</span><span style="font-family:'Times New Roman'; font-size:11pt">eterinary and medical prescribing should be subj</span><span style="font-family:'Times New Roman'; font-size:11pt">ect to intelligent overview by colleagues and regulators and those prescribing poorly should receive additional training.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">7</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">.3</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">We welcome the commitment to encourage the training of farmers. However, it is important </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">this</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> is balanced and independent. Since t</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">he ban on advertising antimicrobials </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">in farming journals</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> came into force in October 2013, some phar</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">maceutical companies have been holding </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">seminars for farmers to improve their understanding </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">of </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">respons</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">ible antimicrobial use. That is not a substitute for </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">training</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">,</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> as they will inevitably use </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">these as commercial opportunities</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> to promote their products</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">.</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">7</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">.4</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">We welcome the commitments on surveillance for AMR</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">,</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> but it is </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">also </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">essential that data be </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">collected on</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> how much of </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">each </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">antimicrobial class is used </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">in </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">each</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> species</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">.</span><br /><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Broader concerns about the strategy</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.5</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">We welcome the commitment to advocate minimizing routine preventative antimicrobial use but this does not go far enough. </span><span style="font-family:'Times New Roman'; font-size:11pt">This</span><span style="font-family:'Times New Roman'; font-size:11pt"> practice </span><span style="font-family:'Times New Roman'; font-size:11pt">still </span><span style="font-family:'Times New Roman'; font-size:11pt">is still widespread</span><span style="font-family:'Times New Roman'; font-size:11pt"> and the </span><span style="font-family:'Times New Roman'; font-size:11pt">underlying</span><span style="font-family:'Times New Roman'; font-size:11pt"> cause of </span><span style="font-family:'Times New Roman'; font-size:11pt">most</span><span style="font-family:'Times New Roman'; font-size:11pt"> resist</span><span style="font-family:'Times New Roman'; font-size:11pt">ance problem on farms</span><span style="font-family:'Times New Roman'; font-size:11pt">. It is</span><span style="font-family:'Times New Roman'; font-size:11pt"> primarily undertaken for commercial not clinical reasons. </span><span style="font-family:'Times New Roman'; font-size:11pt">There would be less need for CIAs if other antimicrobials were not abused in this way. </span><span style="font-family:'Times New Roman'; font-size:11pt">In addition, a</span><span style="font-family:'Times New Roman'; font-size:11pt">lthough growth promotion has been banned, </span><span style="font-family:'Times New Roman'; font-size:11pt">some</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">antibiotics can still</span><span style="font-family:'Times New Roman'; font-size:11pt"> be</span><span style="font-family:'Times New Roman'; font-size:11pt"> used at growth-promoting levels as a low cost insurance against the risk of possible disease.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">In addition, almost all dairy cows are routinely treated with antibiotics in attempts to prevent mastitis.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.6</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">The inclusion of antibiotics in the feed or wa</span><span style="font-family:'Times New Roman'; font-size:11pt">ter of herds or flocks of animals accounts for over 85% of farm antibiotic use in the UK </span><span style="font-family:'Times New Roman'; font-size:11pt">[33]</span><span style="font-family:'Times New Roman'; font-size:11pt">, in contrast to Sweden where </span><span style="font-family:'Times New Roman'; font-size:11pt">it</span><span style="font-family:'Times New Roman'; font-size:11pt"> account</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> for 12</span><span style="font-family:'Times New Roman'; font-size:11pt">%</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[34]</span><span style="font-family:'Times New Roman'; font-size:11pt">. Many of these antibiotic products are licensed for preventative treatment, and in some cases there is no requirement that any disease be diagnosed. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.7</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">In t</span><span style="font-family:'Times New Roman'; font-size:11pt">he past year, both the Government and the VMD have stated that they do not approve of the routine use of antibiotics for disease prevention</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[35]</span><span style="font-family:'Times New Roman'; font-size:11pt">[36]</span><span style="font-family:'Times New Roman'; font-size:11pt">, and in </span><span style="font-family:'Times New Roman'; font-size:11pt">2011 the European Medicines Agency issued a statement which discourages routine use </span><span style="font-family:'Times New Roman'; font-size:11pt">[37]</span><span style="font-family:'Times New Roman'; font-size:11pt">. Very recently, a new scientific commission launched by </span><span style="font-family:'Times New Roman'; font-size:11pt">the journal </span><span style="font-family:'Times New Roman'; font-size:11pt">Lancet Infectious Diseases recommended that routine preventative use in farming of medically important antibiotics be phased out</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[21]</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.8</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Despite these concerns</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> numerous veterinary antibiotic products may still be used routine</span><span style="font-family:'Times New Roman'; font-size:11pt">ly.</span><span style="font-family:'Times New Roman'; font-size:11pt"> A timetable to phase out this practice in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> should be included in the strategy</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> This would not </span><span style="font-family:'Times New Roman'; font-size:11pt">prevent </span><span style="font-family:'Times New Roman'; font-size:11pt">the metaphylactic (</span><span style="font-family:'Times New Roman'; font-size:11pt">preventative</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> use of antimicrobials when disease has been identified in </span><span style="font-family:'Times New Roman'; font-size:11pt">some animals in </span><span style="font-family:'Times New Roman'; font-size:11pt">a herd or flock.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.9</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">The implementation of the strategy is to be led by</span><span style="font-family:'Times New Roman'; font-size:11pt"> a new ‘</span><span style="font-family:'Times New Roman'; font-size:11pt">Interdepartmental High-level Steering Group’. We see no </span><span style="font-family:'Times New Roman'; font-size:11pt">difference </span><span style="font-family:'Times New Roman'; font-size:11pt">between this and the interdepartmental steering group that has presided over a period of spectacular increases in AMR</span><span style="font-family:'Times New Roman'; font-size:11pt"> developments in farm animals.</span><span style="font-family:'Times New Roman'; font-size:11pt"> As such </span><span style="font-family:'Times New Roman'; font-size:11pt">independent</span><span style="font-family:'Times New Roman'; font-size:11pt"> oversight with teeth is </span><span style="font-family:'Times New Roman'; font-size:11pt">needed</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.10 The need for an over-arching independent scientifi</span><span style="font-family:'Times New Roman'; font-size:11pt">c committee to embrace both human and veterinary medicine were key recommendations of the Swann Committee report in 1969 and the House of Lords’ report in 1998. In both cases the Governments of the day took several years to set up the committees, overloade</span><span style="font-family:'Times New Roman'; font-size:11pt">d them with </span><span style="font-family:'Times New Roman'; font-size:11pt">relatively minor</span><span style="font-family:'Times New Roman'; font-size:11pt"> tasks, failed to provide them with adequate resources</span><span style="font-family:'Times New Roman'; font-size:11pt"> to consider the bigger picture</span><span style="font-family:'Times New Roman'; font-size:11pt">, then when there was little media interest in AMR, quietly wound </span><span style="font-family:'Times New Roman'; font-size:11pt">them </span><span style="font-family:'Times New Roman'; font-size:11pt">up. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.11</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">he need for such a committee is even greater today</span><span style="font-family:'Times New Roman'; font-size:11pt"> and we re</span><span style="font-family:'Times New Roman'; font-size:11pt">co</span><span style="font-family:'Times New Roman'; font-size:11pt">mmend that one should be set up. To</span><span style="font-family:'Times New Roman'; font-size:11pt"> avoid history repeating itself </span><span style="font-family:'Times New Roman'; font-size:11pt">there also needs to be a </span><span style="font-family:'Times New Roman'; font-size:11pt">new </span><span style="font-family:'Times New Roman'; font-size:11pt">permanent</span><span style="font-family:'Times New Roman'; font-size:11pt"> Parliamentary committee </span><span style="font-family:'Times New Roman'; font-size:11pt">to monitor</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">AMR issue and </span><span style="font-family:'Times New Roman'; font-size:11pt">the Government’s progress in addressing it</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">The process initiated by the House of Lords committee </span><span style="font-family:'Times New Roman'; font-size:11pt">i</span><span style="font-family:'Times New Roman'; font-size:11pt">n 1998 </span><span style="font-family:'Times New Roman'; font-size:11pt">came to an end in 2001, just at the point when continuing scrutiny </span><span style="font-family:'Times New Roman'; font-size:11pt">could have prevented some of the most serious AMR developments</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.12</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">A major concern about the strategy is the role given to the VMD in jointly providing </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">lead on implementation </span><span style="font-family:'Times New Roman'; font-size:11pt">with PHE. Although the strategy states ‘The Department of Health, with support from PHE </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">and Defra </span><span style="font-family:'Times New Roman'; font-size:11pt">[our emphasis],</span><span style="font-family:'Times New Roman'; font-size:11pt"> will lead on implementation of the Strategy’, this is misleading since responsibility for AMR was taken from Defra in April 2011 and handed to</span><span style="font-family:'Times New Roman'; font-size:11pt"> the VMD.</span><span style="font-family:'Times New Roman'; font-size:11pt"> It is therefore the VMD, </span><span style="font-family:'Times New Roman'; font-size:11pt">not</span><span style="font-family:'Times New Roman'; font-size:11pt"> Defra, that will be </span><span style="font-family:'Times New Roman'; font-size:11pt">lead</span><span style="font-family:'Times New Roman'; font-size:11pt">ing</span><span style="font-family:'Times New Roman'; font-size:11pt"> on the veterinary side</span><span style="font-family:'Times New Roman'; font-size:11pt">. It </span><span style="font-family:'Times New Roman'; font-size:11pt">was the VMD, not Defra, that was involved in drawing up the Strategy (see p3 of Strategy).</span><span style="font-family:'Times New Roman'; font-size:11pt"> Motives for this obfuscation should be considered.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.13 </span><span style="font-family:'Times New Roman'; font-size:11pt">Although the </span><span style="font-family:'Times New Roman'; font-size:11pt">VMD is efficient</span><span style="font-family:'Times New Roman'; font-size:11pt"> and very professional,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and has addressed a number of longstanding abuses of veterinary medicines over the past year, it</span><span style="font-family:'Times New Roman'; font-size:11pt"> is not suited to this </span><span style="font-family:'Times New Roman'; font-size:11pt">primary</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">leadership role </span><span style="font-family:'Times New Roman'; font-size:11pt">on the veterinary side </span><span style="font-family:'Times New Roman'; font-size:11pt">due to its </span><span style="font-family:'Times New Roman'; font-size:11pt">lack of democratic accountability and i</span><span style="font-family:'Times New Roman'; font-size:11pt">nherent conflict</span><span style="font-family:'Times New Roman'; font-size:11pt"> of interest</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> in </span><span style="font-family:'Times New Roman'; font-size:11pt">the way in which it was established</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> in 1989</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> as a self-funding agency, as part of moves to ‘roll back the state’ and remove regulatory burdens on industry.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">As </span><span style="font-family:'Times New Roman'; font-size:11pt">explained below, </span><span style="font-family:'Times New Roman'; font-size:11pt">this </span><span style="font-family:'Times New Roman'; font-size:11pt">make</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> it excessively vulnerable to influe</span><span style="font-family:'Times New Roman'; font-size:11pt">nce and lobbying, particularly </span><span style="font-family:'Times New Roman'; font-size:11pt">by</span><span style="font-family:'Times New Roman'; font-size:11pt"> the pharmaceutical industry.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Similar concerns have been expressed in relation to the regulation of human medicines</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[38]</span><span style="font-family:'Times New Roman'; font-size:11pt">, however </span><span style="font-family:'Times New Roman'; font-size:11pt">neither the Department of Health nor </span><span style="font-family:'Times New Roman'; font-size:11pt">PHE</span><span style="font-family:'Times New Roman'; font-size:11pt">, which lead the implementation of the AMR strategy on the medical side</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> have no</span><span style="font-family:'Times New Roman'; font-size:11pt"> financial conflict of interests</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> since</span><span style="font-family:'Times New Roman'; font-size:11pt"> their funding comes from central Government</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.14 In 2011-12, 79% of the VMD’s </span><span style="font-family:'Times New Roman'; font-size:11pt">£14.3 million </span><span style="font-family:'Times New Roman'; font-size:11pt">in</span><span style="font-family:'Times New Roman'; font-size:11pt">come came from the industries it regulates, with two thirds of this coming from pharmaceutical companies</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> mostly for </span><span style="font-family:'Times New Roman'; font-size:11pt">licensing work</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[39]</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">However, under the EU’s Mutual Recognition and Decentralised procedures, the VMD must compete with other EU national licensing bodies to attract applications, </span><span style="font-family:'Times New Roman'; font-size:11pt">because</span><span style="font-family:'Times New Roman'; font-size:11pt"> the pharmaceutical comp</span><span style="font-family:'Times New Roman'; font-size:11pt">anies </span><span style="font-family:'Times New Roman'; font-size:11pt">can choose which</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">EU </span><span style="font-family:'Times New Roman'; font-size:11pt">licensing body to work with</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[40]</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.15</span><span style="font-family:'Times New Roman'; font-size:11pt"> This competitive licensing situation ensures that the VMD must appear attractive to pharmaceutical</span><span style="font-family:'Times New Roman'; font-size:11pt"> companies and creates a conflict of interest. The VMD clearly recognises that its finances depend on companies viewing it favourably and says in its latest Business Plan that one of its priorities is to </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">‘</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Ensure that the veterinary pharmaceutical industry </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">consider the level of service</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">provided by the VMD to be good or e</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">xcellent’. And it explains why this is important by saying </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">‘To enable an increased percentage of EU work to</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">come via the VMD we need to measure and understand the views of our</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">customers so we</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> can understand any barriers to being the agency of choice’</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">[41]</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.16</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">A</span><span style="font-family:'Times New Roman'; font-size:11pt"> further area of concern is that</span><span style="font-family:'Times New Roman'; font-size:11pt"> the VMD states, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">‘</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">In 2013/14 we will be</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">working with other suitable organisations and assurance schemes that we have</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">identified, to consider delegating the responsibility for inspections to them</span><span style="font-family:'Times New Roman'; font-size:11pt">’</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[41]</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> This raises the question</span><span style="font-family:'Times New Roman'; font-size:11pt"> of whether it is appropriate </span><span style="font-family:'Times New Roman'; font-size:11pt">for a largely</span><span style="font-family:'Times New Roman'; font-size:11pt"> industry-funded regulator</span><span style="font-family:'Times New Roman'; font-size:11pt"> to</span><span style="font-family:'Times New Roman'; font-size:11pt"> delegate regulation </span><span style="font-family:'Times New Roman'; font-size:11pt">to a wholly-</span><span style="font-family:'Times New Roman'; font-size:11pt">industry</span><span style="font-family:'Times New Roman'; font-size:11pt"> body</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> over the use of products </span><span style="font-family:'Times New Roman'; font-size:11pt">where</span><span style="font-family:'Times New Roman'; font-size:11pt"> profit is such </span><span style="font-family:'Times New Roman'; font-size:11pt">a strong motivating factor? </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">7.17</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">The VMD </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">also </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">states it, ‘We will continue to consult our customers and interest groups at the</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">earliest stage during development of policy and strategy and invite them to put</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">forward proposals for the development of effect</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">ive regulatory mechanisms</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">.’ </span><span style="font-family:'Times New Roman'; font-size:11pt">We question whether it is appropriate for the VMD to be </span><span style="font-family:'Times New Roman'; font-size:11pt">the arbiter</span><span style="font-family:'Times New Roman'; font-size:11pt"> on policy </span><span style="font-family:'Times New Roman'; font-size:11pt">and strategy</span><span style="font-family:'Times New Roman'; font-size:11pt"> in relation to AMR</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> given it</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> vulnerability to industry influence?</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.18</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">The VMD states it ‘</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">will be actively involved in the</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">discussion required to promote the use of veterinary medicines in preventing</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">disease in order to maximise productivity’ </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">[41]</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">[p6]</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">And, ‘In </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">all</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">cases the VMD will work to influence the legislation to ensure that</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">safe and effective veterinary medicines remain available for use in</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">animals and regulatory burdens are kept to the minimum</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">' </span><span style="font-family:'Times New Roman'; font-size:11pt">[41]</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">[p4]</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">This suggests the VMD has one message for the indu</span><span style="font-family:'Times New Roman'; font-size:11pt">stry which wants to </span><span style="font-family:'Times New Roman'; font-size:11pt">retain preventative use and market</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> antimicrobials</span><span style="font-family:'Times New Roman'; font-size:11pt"> to maximise farm productivity</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and another for a more general audi</span><span style="font-family:'Times New Roman'; font-size:11pt">ence </span><span style="font-family:'Times New Roman'; font-size:11pt">[36]</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">7.19</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">The VMD had a large number of meetings last year with industry representatives. Fifty of these related to licensing issues, an unspecified number related to policy issues. One of the VMD’s roles, for which Defra pays it £3 million pa, is ‘the provision and</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> implementation of policy advice to Ministers’. Since Defra no longer has any responsibility for AMR and even its own advisory committee on AMR is chaired and administered by the VMD, Ministers have </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">little</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> alternative but to </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">agree to</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> the advice the VMD giv</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">es them. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">This</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> means that </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">industry </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">lobbying </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">of the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">VMD is </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">essentially equivalent to</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> lobbying a Minister. This is inappropriate</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">,</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">especially at the present time when the industry </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">is fighting to oppose</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> moves to end routine prophylactic use of antimicrobials</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">[42]</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7.20</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">The VMD is also responsible for the Government’s assessment of the significance of veterinary antimicrobial use </span><span style="font-family:'Times New Roman'; font-size:11pt">to AMR</span><span style="font-family:'Times New Roman'; font-size:11pt"> in infections affecting humans. </span><span style="font-family:'Times New Roman'; font-size:11pt">In </span><span style="font-family:'Times New Roman'; font-size:11pt">the 5-year Strategy</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> this</span><span style="font-family:'Times New Roman'; font-size:11pt"> begins with the statement, ‘</span><span style="font-family:'Times New Roman'; font-size:11pt">Increasing scientific evidence suggests that the clinical issues with antimicrobial resistance that we face in human medicine are primarily the result of antibiotic use in people, rather than the use of</span><span style="font-family:'Times New Roman'; font-size:11pt"> antibiotics in animals.</span><span style="font-family:'Times New Roman'; font-size:11pt">’ The VMD has produced several similar statements before. The statement may be correct overall but it is </span><span style="font-family:'Times New Roman'; font-size:11pt">highly </span><span style="font-family:'Times New Roman'; font-size:11pt">misleading and creates the impression there is no significant farm dimension</span><span style="font-family:'Times New Roman'; font-size:11pt"> to the AMR problem</span><span style="font-family:'Times New Roman'; font-size:11pt">, when closer examination</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">of following text and the science </span><span style="font-family:'Times New Roman'; font-size:11pt">shows there </span><span style="font-family:'Times New Roman'; font-size:11pt">clearly </span><span style="font-family:'Times New Roman'; font-size:11pt">is. In response </span><span style="font-family:'Times New Roman'; font-size:11pt">Farmers Guardian told its readers, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">‘</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; font-style:italic">Antimicrobial resistance seen in human medicine is primarily the result of antibiotic use in people, rather than animals, a major Government report h</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; font-style:italic">as stated’</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">[43]</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">.</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">There are many similar examples</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">.</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> The VMD’s approach </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">is at odds with concerns expressed in many countries and </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">designed to please </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">its main sources of funding. More seriously</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">,</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> the phrasing of such statements </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">re-enforces entrenched views and </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">seriously</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> undermine</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">s</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt"> efforts to </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">reduce AMR in farm animals through more judicious use of antimicrobials</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><h2 style="font-size:11pt; line-height:115%; margin:10pt 0pt 0pt; page-break-after:avoid; page-break-inside:avoid; text-align:justify"><span style="color:#4f81bd; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">References</span></h2><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-30.83pt"><span style="font-family:'Times New Roman'; font-size:11pt">[1]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372559061"></a><a name="_Ref371584920"></a><a name="_Ref346872663"></a><a name="_Ref347923655"><span style="font-family:'Times New Roman'; font-size:11pt">House of Lords Science and Technology Committee 2001. Third report, 22 March </span></a><a href="http://www.publications.parliament.uk/pa/ld200001/ldselect/ldsctech/56/5601.htm"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.publications.parliament.uk/pa/ld200001/ldselect/ldsctech/56/5601.htm</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-30.83pt"><span style="font-family:'Times New Roman'; font-size:11pt">[2]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372559085"><span style="font-family:'Times New Roman'; font-size:11pt">Ho</span><span style="font-family:'Times New Roman'; font-size:11pt">use of Lords Science</span><span style="font-family:'Times New Roman'; font-size:11pt"> and Technology Committee</span><span style="font-family:'Times New Roman'; font-size:11pt"> 1998.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Resistance to Antibiotics and Other Antimicrobial Agents, </span></a><a href="http://www.parliament.the-stationery-office.co.uk/pa/ld199798/ldselect/ldsctech/081vii/st0701.htm"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.parliament.the-stationer</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">y-office.co.uk/pa/ld199798/ldselect/ldsctech/081vii/st0701.htm</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-30.83pt"><span style="font-family:'Times New Roman'; font-size:11pt">[3]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371863311"><span style="font-family:'Times New Roman'; font-size:11pt">ACMSF 1999. Report on Microbial Antibiotic Resistance in Relation to Food Safety.</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><a name="_Ref371863488"></a><a href="http://www.food.gov.uk/multimedia/pdfs/committee/acm-1091-amr.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.food.gov.uk/multi</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">media/pdfs/committee/acm-1091-amr.pdf</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-30.83pt"><span style="font-family:'Times New Roman'; font-size:11pt">[4]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371253095"><span style="font-family:'Times New Roman'; font-size:11pt">Taylor et al 2008. A survey of fluoroquinolone resistance in Eschiichia coli and thermophilic Campylobacter spp. On poultry and pig farms in Great Britain, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J Appl</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">ied</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> Microbiol</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">ogy</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">105</span><span style="font-family:'Times New Roman'; font-size:11pt">: 1421-31</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-30.83pt"><span style="font-family:'Times New Roman'; font-size:11pt">[5]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371254184"><span style="font-family:'Times New Roman'; font-size:11pt">Piddock et al, 2003. Fl</span><span style="font-family:'Times New Roman'; font-size:11pt">uoroquinolone resistance in Campylobacter species from man and animals: detection of mutations in topoisomerase genes.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> J Antimicrobial Chemotherapy </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">51</span><span style="font-family:'Times New Roman'; font-size:11pt">: 19-26</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-30.83pt"><span style="font-family:'Times New Roman'; font-size:11pt">[6]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371586164"><span style="font-family:'Times New Roman'; font-size:11pt">Hopkins et al., 2007. </span><span style="font-family:'Times New Roman'; font-size:11pt">Plasmid-mediated quinolone resistance determinant qnrS1 found in Salmonella </span><span style="font-family:'Times New Roman'; font-size:11pt">enterica strains isolated in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Journal of Antimicrobial Chemotherapy</span><span style="font-family:'Times New Roman'; font-size:11pt">, 59: 1071-5</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-30.83pt"><span style="font-family:'Times New Roman'; font-size:11pt">[7]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371587472"><span style="font-family:'Times New Roman'; font-size:11pt">FSA, 2009. FSA report for the UK survey of Campylobacter and Salmonella contamination of fresh chicken at retail sale, </span></a><a href="http://www.foodbase.org.uk/admintools/reportdocuments/351-1-676_B18025.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.foodbase.org.uk/admintools/reportdocuments/351-1-676_B18025.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-30.83pt"><span style="font-family:'Times New Roman'; font-size:11pt">[8]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371587659"><span style="font-family:'Times New Roman'; font-size:11pt">Bean </span><span style="font-family:'Times New Roman'; font-size:11pt">et al.,</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2008. Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005-2006</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">, Annals o</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">f Clinical Microbiology and Antimicrobials</span><span style="font-family:'Times New Roman'; font-size:11pt">, 7:13 </span></a><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440378/pdf/1476-0711-7-13.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440378/pdf/1476-0711-7-13.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-30.83pt"><span style="font-family:'Times New Roman'; font-size:11pt">[9]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371587929"><span style="font-family:'Times New Roman'; font-size:11pt">Public Health Wales, 2011. Antibacterial</span><span style="font-family:'Times New Roman'; font-size:11pt"> resistance and usage in Wales 2005-2010, </span></a><a href="http://www.wales.nhs.uk/news/21018"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.wales.nhs.uk/news/21018</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[10]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372490382"><span style="font-family:'Times New Roman'; font-size:11pt">Nunan and Young, 2012. E. coli superbugs on farms and food. Soil Association </span></a><a href="http://www.soilassociation.org/LinkClick.aspx?fileticket=yCT9su5iViQ%3D&amp;tabid=1841"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.soilassociation.org/LinkClick.aspx?fileticket=yCT9su5iViQ%3D&amp;tabid=1841</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[11]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371672464"><span style="font-family:'Times New Roman'; font-size:11pt">Nunan and Young, 2007. MRSA in farm animals and meat, </span></a><a href="http://www.soilassociation.org/LinkClick.aspx?fileticket=%2BmWBoFr348s%3D&amp;tabid=1326"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.soilassociation.org/LinkClick.aspx?fileticket=%2BmWBoFr348s%3D&amp;tabid=1326</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[12]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371673238"><span style="font-family:'Times New Roman'; font-size:11pt">Paterson et al., 2012. </span><span style="font-family:'Times New Roman'; font-size:11pt">First detection of livestock-associated meticillin-resistant Stap</span><span style="font-family:'Times New Roman'; font-size:11pt">hylococcus aureus CC398 in bulk tank milk in the United Kingdom, January to July 2012</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Euro Surveillance</span><span style="font-family:'Times New Roman'; font-size:11pt">, 17:</span><span style="font-family:'Times New Roman'; font-size:11pt"> pii: 20337</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span></a><a href="http://www.eurosurveillance.org/images/dynamic/EE/V17N50/art20337.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.eurosurveillance.org/images/dynamic/EE/V</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">17N50/art20337.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[13]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372528979"><span style="font-family:'Times New Roman'; font-size:11pt">Loeffler et al.</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">2009. </span><span style="font-family:'Times New Roman'; font-size:11pt">First isolation of MRSA ST398 from UK animals:  a new challenge for infection control teams? J Hosp Infect.  2009;72(3):269-71</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[14]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371700194"><span style="font-family:'Times New Roman'; font-size:11pt">Defra Antimicrobial Resistance Coordination Group (DARC), 2012. Report of meeting held on 1 February 2012, </span></a><a href="http://www.vmd.defra.gov.uk/pdf/darc_mrsa_MinsFeb12.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.vmd.defra.gov.uk/pdf/darc_mrsa_MinsFeb12.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[15]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371673117"><span style="font-family:'Times New Roman'; font-size:11pt">García-Álvarez et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. 2011, </span><span style="font-family:'Times New Roman'; font-size:11pt">Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet Infectious Diseases</span><span style="font-family:'Times New Roman'; font-size:11pt">, 11: 595-603, </span></a><a href="http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2811%2970126-8/fulltext"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2811%2970126-8/fulltext</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[16]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371694183"><span style="font-family:'Times New Roman'; font-size:11pt">Paterson et al., 2013. </span><span style="font-family:'Times New Roman'; font-size:11pt">Prevalence and properties of mecC methicillin-resistant Staphylococcus aureus (MRSA) in bovine bulk ta</span><span style="font-family:'Times New Roman'; font-size:11pt">nk milk in Great Britain</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Journal of Antimicrobial Chemotherapy</span><span style="font-family:'Times New Roman'; font-size:11pt">, October 2013, </span></a><a href="http://jac.oxfordjournals.org/content/early/2013/10/22/jac.dkt417.full.pdf+html"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://jac.oxfordjournals.org/content/early/2013/10/22/jac.dkt417.full.pdf+html</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[17]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371701031"><span style="font-family:'Times New Roman'; font-size:11pt">Petersen et al., 2013. </span><span style="font-family:'Times New Roman'; font-size:11pt">Epidemiology of methicillin-resistant Staphylococcus aureus carrying the novel mecC gene in Denmark corroborates a zoonotic reservoir with transmission to humans</span><span style="font-family:'Times New Roman'; font-size:11pt">, 19:</span><span style="font-family:'Times New Roman'; font-size:11pt">16-22</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span></a><a href="http://onlinelibrary.wiley.com/doi/10.1111/1469-0691.12036/pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://onlinelibrary.wiley.com/doi/10.1111/1469-0691.12036/pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[18]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371702399"><span style="font-family:'Times New Roman'; font-size:11pt">Poirel et al.</span><span style="font-family:'Times New Roman'; font-size:11pt">, 2012.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Carbapenemase</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">producing  Acinetobacte</span><span style="font-family:'Times New Roman'; font-size:11pt">r spp. in cattle, France. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Emerging Infectious  Diseases</span><span style="font-family:'Times New Roman'; font-size:11pt">;  18: 523–5</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span></a><a href="http://wwwnc.cdc.gov/eid/server-error.htm?aspxerrorpath=/eid/article/18/3/pdfs/11-1330.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://wwwnc.cdc.gov/eid/server-error.htm?aspxerrorpath=/eid/article/18/3/pdfs/11-1330.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[19]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371701754"><span style="font-family:'Times New Roman'; font-size:11pt">Fisher et al., 2013. </span><span style="font-family:'Times New Roman'; font-size:11pt">Escherichia coli producing VIM-1  ca</span><span style="font-family:'Times New Roman'; font-size:11pt">rbapenemase isolated on a pig farm</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Journal of Antimicrobial Chemotherapy</span><span style="font-family:'Times New Roman'; font-size:11pt">, 67</span><span style="font-family:'Times New Roman'; font-size:11pt">:1793-5</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span></a><a href="http://jac.oxfordjournals.org/content/67/7/1793.full.pdf+html"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://jac.oxfordjournals.org/content/67/7/1793.full.pdf+html</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[20]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371701756"><span style="font-family:'Times New Roman'; font-size:11pt">Fisher et al., 2012. </span><span style="font-family:'Times New Roman'; font-size:11pt">Salmonel</span><span style="font-family:'Times New Roman'; font-size:11pt">la enterica subsp. enterica producing VIM-1 carbapenemase isolated from livestock farms</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Journal of Antimicrobial Chemotherapy</span><span style="font-family:'Times New Roman'; font-size:11pt">, ;68</span><span style="font-family:'Times New Roman'; font-size:11pt">:478-80 </span></a><a href="http://jac.oxfordjournals.org/content/early/2012/10/02/jac.dks393.full.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://jac.oxfordjournals.org</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">/content/early/2012/10/02/jac.dks393.full.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[21]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372530161"><span style="font-family:'Times New Roman'; font-size:11pt">Laxminarayan</span><span style="font-family:'Times New Roman'; font-size:11pt"> et al., 2013. Antibiotic resistance – the need for global solutions, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet Infectious Diseases</span><span style="font-family:'Times New Roman'; font-size:11pt">, November 17</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[22]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371702517"><span style="font-family:'Times New Roman'; font-size:11pt">Threlfall, 2010. </span><span style="font-family:'Times New Roman'; font-size:11pt">Is Salmonella 4,[5],12:1:- the next MDR epidemic European Salmonell</span><span style="font-family:'Times New Roman'; font-size:11pt">a?, Paper presented at a Veterinary Laboratories Agency conference at Warwick University 22-24 September 2010</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[23]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371806318"><span style="font-family:'Times New Roman'; font-size:11pt">HPA 2012. Potentially transferable linezolid resistance in Enterococcus faecium in the UK. </span></a><a href="http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317135991530"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317135991530</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[24]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371806351"><span style="font-family:'Times New Roman'; font-size:11pt">Defra Antimicrobial Resistance Co-ordination Group</span><span style="font-family:'Times New Roman'; font-size:11pt">, 2010. Report of the 38th Meeting, 27 April para 6.3 </span></a><a href="http://www.vmd.defra.gov.uk/pdf/darc_MinsApril10.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">ht</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">tp://www.vmd.defra.gov.uk/pdf/darc_MinsApril10.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[25]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371702745"><span style="font-family:'Times New Roman'; font-size:11pt">Defra Antimicrobial Resistance Co-ordinati</span><span style="font-family:'Times New Roman'; font-size:11pt">on Group, 2011. Report of 41st M</span><span style="font-family:'Times New Roman'; font-size:11pt">eeting 3 May 2011, </span></a><a href="http://www.vmd.defra.gov.uk/pdf/darc_MinsMay11.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.vmd.defra.gov.uk/pdf/darc_MinsMay</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">11.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[26]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372571908"><span style="font-family:'Times New Roman'; font-size:11pt">EMA 2012, Draft Reflection paper on use of pleuromutilins in food-producing animals in the European Union: development of resistance and impact on human and animal health </span></a><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/12/WC500136418.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/12/WC500136418.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[27]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371790026"><span style="font-family:'Times New Roman'; font-size:11pt">Jake Waddilove 2009. The anatomy of a regional swine dysentery outbreak. Pig World August, pp 42-3</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[28]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372549301"><span style="font-family:'Times New Roman'; font-size:11pt">VMD 2013. UK </span><span style="font-family:'Times New Roman'; font-size:11pt">Veterinary Ant</span><span style="font-family:'Times New Roman'; font-size:11pt">i</span><span style="font-family:'Times New Roman'; font-size:11pt">biotic Resistance and Sales Surveillance 2012 </span></a><a href="http://www.vmd.defra.gov.uk/pdf/varss.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.vmd.defra.gov.uk/pdf/varss.pdf</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[29]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371412256"></a><a name="_Ref372478104"><span style="font-family:'Times New Roman'; font-size:11pt">Corpet, 1988. </span><span style="font-family:'Times New Roman'; font-size:11pt">Antibiotic resistance from food</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">The New England Journal of Medicine</span><span style="font-family:'Times New Roman'; font-size:11pt">, 318: 1206-7</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span></a><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814222/"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814222/</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[30]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372563786"><span style="font-family:'Times New Roman'; font-size:11pt">Defra 2004.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="color:#000033; font-family:'Times New Roman'; font-size:11pt">The effect of antimicrobial treatment and withdrawal on the population dynamics of enteric bacteria expressing resistanc</span><span style="color:#000033; font-family:'Times New Roman'; font-size:11pt">e in the pig </span></a><a href="http://www.msffg.org.uk/project.php?pid=636"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.msffg.org.uk/project.php?pid=636</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[31]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372565647"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Defra 2008. Antimicrobial resistance: an evaluation of risk factors to identify control strategies, Defra project code OD2015</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[32]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372479645"><span style="font-family:'Times New Roman'; font-size:11pt">Veterinary L</span><span style="font-family:'Times New Roman'; font-size:11pt">aboratories Agency, 2006. Investigation of persistence of antimicrobial resistant organisms in livestock production, Project OD2006, </span></a><a href="http://randd.defra.gov.uk/Default.aspx?Menu=Menu&amp;Module=More&amp;Location=None&amp;C%20ompleted=0&amp;ProjectID=9902"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http:</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">//randd.defra.gov.uk/Default.aspx?Menu=Menu&amp;Module=More&amp;Location=None&amp;C%20ompleted=0&amp;ProjectID=9902</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[33]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372486693"><span style="font-family:'Times New Roman'; font-size:11pt">VMD, 2012. Sales of antimicrobial products authorized for use as veterinary medicines in the UK in 2011, </span></a><a href="http://www.vmd.defra.gov.uk/pdf/salesanti11.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.vmd.defra.gov.uk/pdf/salesanti11.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[34]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372487538"><span style="font-family:'Times New Roman'; font-size:11pt">European Medicines Agency, 2013. </span><span style="font-family:'Times New Roman'; font-size:11pt">Sales of veterinary  antimicrobial agents in  25 EU/EEA countries in  2011</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span></a><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/10/WC500152311.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/10/WC500152311.pdf</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[35]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref371707660"><span style="font-family:'Times New Roman'; font-size:11pt">Hansard, 2013. </span></a><a href="http://www.publications.parliament.uk/pa/cm201213/cmhansrd/cm130109/halltext/130109h0002.htm#13010947000001"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.publications.parliament.uk/pa/cm201213/cmhansrd/cm130109/halltext/130109h0002.htm#13010947000001</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[36]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372487834"><span style="font-family:'Times New Roman'; font-size:11pt">VMD, 2013. VMD and VPC open meeting information pack, </span></a><a href="http://www.vmd.defra.gov.uk/pdf/VMD_VPC_InfoPack.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.vmd.defra.gov.uk/pdf/VMD_VPC_InfoPack.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[37]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372488716"><span style="font-family:'Times New Roman'; font-size:11pt">CVMP, 2011. </span><span style="font-family:'Times New Roman'; font-size:11pt">What does CVMP mean by “treatment and prevention”?</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span></a><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/07/WC500109155.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/07/WC500109155.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span><a name="_Ref372230493"></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[38]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372568294"><span style="font-family:'Times New Roman'; font-size:11pt">Evans and Boseley 2014. The drugs industry and its watchdog: a relationship too close for comfort? The Guardian 4 October </span></a><a href="http://www.theguardian.com/society/2004/oct/04/health.businessofresearch1"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.theguardian.com/society/2004/oct/04/health.businessofresearch1</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[39]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372163743"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">VMD 2012</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">. Veterinary Medicines Directorate Annual Report and Accounts 2011/12 </span></a><a href="http://www.vmd.defra.gov.uk/pdf/annualreport/vmdanrep11.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.vmd.defra.gov.uk/pdf/annualreport/vmdanrep11.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[40]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372503591"></a><a name="_Ref372170506"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">VMD 2013. Controls of Veter</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">inary Medicines, sections p14</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none"> </span></a><a href="http://www.vmd.defra.gov.uk/pdf/vmgn/VMGNote01.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.vmd.defra.gov.uk/pdf/</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">vmgn/VMGNote01.pdf</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[41]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372503496"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">VMD 2013. Veterinary Medicines Directorate Business Plan 2013/14 to 2014/15 and forward look, section 9.2 </span></a><a href="http://www.vmd.defra.gov.uk/pdf/BusinessPlan.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.vmd.defra.gov.uk/pdf/BusinessPlan.pdf</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[42]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372504604"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">RUMA 2013. </span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">RUMA position statement on the preventative use of antibiotics in farm animals</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></a><a href="http://www.ruma.org.uk/news/20130307.htm"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.ruma.org.uk/news/20130307.htm</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36.33pt; text-align:justify; text-indent:-36.33pt"><span style="font-family:'Times New Roman'; font-size:11pt">[43]</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><a name="_Ref372504966"><span style="font-family:'Times New Roman'; font-size:11pt">Alistair Driver 2013. Human medicine the ‘prime cause off antimicrobial resista</span><span style="font-family:'Times New Roman'; font-size:11pt">nce’ Farmers Guardian 10 September</span><span style="font-family:'Times New Roman'; font-size:11pt"> p7 </span></a><a href="http://www.farmersguardian.com/home/hot-topics/antibiotics/human-medicine-the-prime-cause-of-antimicrobial-resistance/58651.article"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.farmersguardian.com/home/hot-topics/antibiotics/human-medicine</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">-the-prime-cause-of-antimicrobial-resistance/58651.article</span></a></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div></body></html>